Quick Answer
Emergent BioSolutions Inc. reported Long-Term Debt of $589.70 million for fiscal year 2025.
Emergent BioSolutions Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $589.70M | -15.8% |
| 2024 | $700.00M | +56.8% |
| 2023 | $446.50M | -0.4% |
| 2022 | $448.50M | -44.6% |
| 2021 | $809.40M | -3.8% |
| 2020 | $841.00M | +5.3% |
| 2019 | $798.40M | +1.8% |
| 2018 | $784.50M | +5711.1% |
| 2017 | $13.50M | -94.6% |
| 2016 | $248.09M | +0.5% |
| 2015 | $246.89M | -1.6% |
| 2014 | $251.00M | +304.8% |
| 2013 | $62.00M | +6.3% |
| 2012 | $58.30M | +7.8% |
| 2011 | $54.09M | +78.9% |
| 2010 | $30.24M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $663.10M | +0.2% | -0.7% |
| June 30, 2025 | $667.80M | +49.4% | +0.3% |
| March 31, 2025 | $665.70M | +49.0% | +0.3% |
| December 31, 2024 | $663.70M | +48.6% | +0.3% |
| September 30, 2024 | $661.80M | +47.7% | +48.1% |
| June 30, 2024 | $447.00M | -0.2% | +0.1% |
| March 31, 2024 | $446.70M | -0.2% | +0.0% |
| December 31, 2023 | $446.50M | -0.4% | -0.4% |
- Emergent BioSolutions Inc. showed a decrease of -15.8% in Long-Term Debt compared to the prior fiscal year.
- Over the 2010–2025 period, Emergent BioSolutions Inc.’s long-term debt has grown by 1850.1% (from $30.24 million to $589.70 million).
- The most recent figure is from Emergent BioSolutions Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: